In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.

Authors :: Werngren J
Wijkander M
Perskvist N
Balasubramanian V
Sambandamurthy VK
Rodrigues C
Hoffner S
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014 Jul; Vol. 58 (7), pp. 4222-3. Date of Electronic Publication: 2014 Apr 28.
Publication Year :: 2014
Abstract: The MIC of the novel antituberculosis (anti-TB) drug AZD5847 was determined against 146 clinical isolates from diverse geographical regions, including eastern Europe, North America, Africa, and Asia, using the automated Bactec Mycobacterial Growth Indicator Tube (MGIT) 960 system. These isolates originated from specimen sources such as sputum, bronchial alveolar lavage fluid, pleural fluid, abscess material, lung biopsies, and feces. The overall MIC90 was 1.0 mg/liter (range, 0.125 to 4 mg/liter). The MICs of AZD5847 for isolates of Mycobacterium tuberculosis were similar among drug-sensitive strains, multidrug-resistant (MDR) strains, and extensively drug resistant (XDR) strains. The good in vitro activity of AZD5847 against M. tuberculosis and the lack of cross-resistance make this agent a promising anti-TB drug candidate.<br /> (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)

Subjects :: Drug Resistance, Multiple, Bacterial
Extensively Drug-Resistant Tuberculosis microbiology
Humans
Microbial Sensitivity Tests
Mycobacterium tuberculosis genetics
Mycobacterium tuberculosis isolation & purification
Tuberculosis, Pulmonary microbiology
Antitubercular Agents therapeutic use
Extensively Drug-Resistant Tuberculosis drug therapy
Mycobacterium tuberculosis drug effects
Oxazolidinones therapeutic use
Tuberculosis, Pulmonary drug therapy

Full Text Access

Tools